This editorial refers to 'Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial' † , by D. Sibbing et al., on page 2749.
1
DAPT includes prasugrel or ticagrelor, both shown to be superior to clopidogrel in addition to aspirin, to avoid ischaemic complications after ACS. 2, 3 Clopidogrel on top of aspirin is even only recommended in patients who cannot receive ticagrelor or prasugrel, including those with prior intracranial bleeding or requiring anticoagulation. 1 However, a profound platelet inhibition is particularly beneficial early after revascularization, while bleeding complications can occur over a more prolonged period. Several alternative strategies have been proposed to retain the efficacious antithrombotic activity of both potent P 2 Y 12 inhibitors, while keeping the lower longterm bleeding risk of clopidogrel. One of these strategies, called deescalation, consists of switching from the potent P 2 Y 12 inhibitor early after the acute event to the less potent agent clopidogrel at some later time point, but usually well before the recommended standard 1-year discontinuation of DAPT. Several clinical trials have tested this strategy. The Timing Of Plaletet Inhibition after acute Coronary syndrome (TOPIC) study was the first to investigate the switch from prasugrel or ticagrelor to clopidogrel vs. continuing either drug after PCI in 646 ACS patients. 4 Finally, in the TROPICAL ACS trial, de-escalation to clopidogrel in the maintenance phase was guided by the results of platelet function tests (PFTs) performed 14 days after PCI in patients receiving prasugrel for 7 days and clopidogrel for an additional 7 days prior to the PFT. 7 The primary endpoint (cardiovascular death, myocardial infarction, stroke, or bleeding BARC > _2) was non-inferior in the guided de-escalation group compared with the control group (7% vs. 9% P non-inf = 0.0004). Despite early de-escalation, there was no decrease in bleeding events (5% vs. 6%, P = 0.23) nor an increase in ischaemic events (3% vs. 3%, P non-inf = 0.0115).
In the present issue of the European Heart Journal, Sibbing et al. report a pre-specified subanalysis of the TROPICAL-ACS trial aimed to assess the impact of age on clinical outcomes following PFT-guided deescalation after ACS. 8 In younger patients (age < _70 years, n = 2240), the 1-year incidence of the primary endpoint was lower in the intervention group vs. maintained treatment (5.9% vs. 8.3%; HR 0.70, 95% CI 0.51-0.96, P = 0.03), mainly because of a reduction in bleeding events. When the impact of age as a continuous variable on outcomes was analysed, an incremental relative risk reduction was observed in the primary endpoint by decreasing age (P int = 0.02) in the deescalation group, in relation to a significant reduction in bleeding. When considering an 'optimum' cut-off for age, patients younger than 57 years further exhibit a beneficial effect of de-escalation, again mainly driven by an increased reduction in BARC 2 bleedings. High platelet reactivity (HPR) was observed in 511 patients (39%), of whom 99% were switched back to prasugrel. In the control group, HPR was reported only in 188 patients at 2 weeks (14%), confirming prasugrel's more potent platelet inhibition. The whole benefit appears to be concentrated on a marginal difference in minor BARC 2 bleedings. Nonetheless, the study did not clearly mention whether the avoided bleedings were among prasugrel-or clopidogrel-treated patients. In the elderly patients (70 years old and above), no benefit was observed in the group of patients with de-escalation for the primary endpoint (15.5% vs. 13.6%; P = 0.56), even when some of the elderly patients were treated with the non-evidence-based 5 mg dose of prasugrel. Incidentally, PFT-guided de-escalation was even not associated with a bleeding reduction (10.8% vs. 9.1%, HR 1.23, 95% CI 0.64-2.35, P = 0.54).
The conclusion that younger patients derived a significant net clinical benefit of guided de-escalation appears at best to be an unfounded overstatement, especially since elderly patients were largely excluded from the trial (only 370 patients > _70 years were included, and patients > _80 years were excluded). In this respect, it makes little clinical sense to implement age 57 as the upper limit of expected benefit of a de-escalation strategy; the real-world challenge lies in how to avoid bleeding risk in those over 57, and especially in those over 75 years of age. Still, de-escalation in high bleeding risk elderly patients might still represent an appealing strategy to reduce bleeding complications. However, platelet function monitoring followed by treatment adjustment has failed to improve clinical ischaemic outcomes as well as to limit bleeding complications in elderly patients after ACS. 9 Moreover, up to one-third of the patients initially treated with 5 mg prasugrel were still below the desired platelet inhibition target at day 28. 9 The number of patients within the therapeutic range of platelet inhibition after de-escalation and therapeutic adaptation (after the first PFT) remains currently unknown in TROPICAL-ACS, however. On aggregate, the three de-escalation trials so far only show that a de-escalating strategy can reduce bleeding complications, but none of them was powered to detect a higher incidence of atherothrombotic events with clopidogrel, as would be expected from the large landmark PLATO and TRITON trials. 5 In this respect, it is essential to remember that in both PLATO and TRITON, landmark analyses showed a continuous benefit of ticagrelor or prasugrel over clopidogrel well beyond the initial acute phase. In addition, the benefit in bleeding risk in the de-escalation trials, if any, appears be limited to a reduction in minor bleeding events only. This reduction was observed in the TOPIC trial, 4 but not in the PRAGUE-18 trial. 6 Now a similar reduction is reported in this subanalysis of the TROPICAL-ACS trial, but, surprisingly, the effect seems to be limited to the younger patients only. These results appear somewhat counterintuitive, as younger patients are usually not those at the highest bleeding risk, while they clearly benefit from a prolonged and dual profound antiplatelet regimen in terms of fewer atherothrombotic events including mortality after myocardial infarction. 10 In any case, the present results highlight that the perfect balance between ischaemic and bleeding risk in elderly ACS patients remains an enigma. While switching from potent P 2 Y 12 inhibitors for clopidogrel in the elderly might indeed represent an attractive though theoretical option, it was not associated with any bleeding benefit in TROPICAL-ACS. Also, PFT failed to limit bleeding complications both in the present trial and in the ANTARCTIC trial. Therefore, the TOPIC trial. Switch from ticagrelor to clopidogrel to be continued for an additional 11 months (no subgroup analysis for elderly patients available). current ESC recommendation not to use PFT routinely to guide antiplatelet therapy after stenting for ACS (i.e. grade III or harmful) remains firmly unchallenged. In addition to de-escalation, reducing the duration of DAPT has also been proposed as an alternative strategy to minimize bleeding complications in the elderly. One randomized trial with a sizable population solely consisting of patients 75 years and above, and one large age-based subanalysis from a large trial, have shown no adverse ischaemic consequences of only 1 month DAPT 11 and 6 months DAPT, 12 and similar bleedings after an ACS, at least with the latest generation drug-eluting stents when compared with bare metal stents (Take home figure ) . These results perfectly support the current ESC guidelines, in which ACS patients with high bleeding risk (according to the PRECISE DAPT score) are recommended to be treated with shorter DAPT, for a minimum of 6 months (grade IIaB). The benefit of PFT-guided de-escalation, at least in the present subanalysis of the TROPICAL-ACS trial, remains hypothetical in unselected, all-comers, transradial procedures for ACS, and does not appear to provide evidence to modify the current ESC guidelines. In younger ACS patients, a powerful, early, and prolonged platelet inhibition regimen remains the preferred management. Weighing all available evidence, among patients at high bleeding risk, who are very often elderly, a reduced duration of DAPT after a PCI for ACS appears to be more substantiated than a de-escalation approach, even when these trials were also not powered for assessing ischaemic risk as well. PFT-guided modulation of antiplatelet treatment appears once more to be largely useless, and in general unable to prevent bleeding complications in elderly patients.
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